Trial Profile

A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 30 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Aug 2023 Results published in the Cephalalgia
10 Dec 2022 Results of post hoc analysis of two studies(NCT03777059 and NCT03700320) assessing sustained initial responses of 50%, 75%, or 100% reduction in mean monthly migraine days (MMDs) over 12 and 52-weeks of atogepant treatment for episodic migraine presented at the 16th European headache federation COngress
12 Jun 2022 Results of post-hoc analysis of two studies (NCT03777059 & NCT03700320) assessing sustained response to atogepant in individuals with episodic migraine, presented at the 64th Annual Scientific Meeting of the American Headache Society.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com